mlm-car44.1 t-cell
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 27, 2019 (NCT04097301)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD44 antigenImmunity, passive
CD44 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04097301 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2019 | European Commission, MolMed S.p.A., Vita-Salute University of Milano. Italy |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Commission | Government | 1 | 0 | 1 | 2019 |
| MolMed S.p.A. | For profit | 1 | 1 | 1 | 2019 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1